1. Home
  2. SLNG vs IMAB Comparison

SLNG vs IMAB Comparison

Compare SLNG & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNG
  • IMAB
  • Stock Information
  • Founded
  • SLNG 2013
  • IMAB 2014
  • Country
  • SLNG United States
  • IMAB United States
  • Employees
  • SLNG N/A
  • IMAB N/A
  • Industry
  • SLNG Oil/Gas Transmission
  • IMAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLNG Utilities
  • IMAB Health Care
  • Exchange
  • SLNG Nasdaq
  • IMAB Nasdaq
  • Market Cap
  • SLNG 85.4M
  • IMAB 79.9M
  • IPO Year
  • SLNG N/A
  • IMAB 2020
  • Fundamental
  • Price
  • SLNG $7.74
  • IMAB $0.96
  • Analyst Decision
  • SLNG Strong Buy
  • IMAB Strong Buy
  • Analyst Count
  • SLNG 1
  • IMAB 3
  • Target Price
  • SLNG $12.00
  • IMAB $8.00
  • AVG Volume (30 Days)
  • SLNG 30.6K
  • IMAB 286.0K
  • Earning Date
  • SLNG 03-05-2025
  • IMAB 03-13-2025
  • Dividend Yield
  • SLNG N/A
  • IMAB N/A
  • EPS Growth
  • SLNG N/A
  • IMAB N/A
  • EPS
  • SLNG 0.21
  • IMAB N/A
  • Revenue
  • SLNG $74,044,000.00
  • IMAB $569,464.00
  • Revenue This Year
  • SLNG N/A
  • IMAB N/A
  • Revenue Next Year
  • SLNG N/A
  • IMAB N/A
  • P/E Ratio
  • SLNG $36.96
  • IMAB N/A
  • Revenue Growth
  • SLNG N/A
  • IMAB N/A
  • 52 Week Low
  • SLNG $3.77
  • IMAB $0.84
  • 52 Week High
  • SLNG $8.28
  • IMAB $2.00
  • Technical
  • Relative Strength Index (RSI)
  • SLNG 62.53
  • IMAB 45.33
  • Support Level
  • SLNG $7.12
  • IMAB $0.95
  • Resistance Level
  • SLNG $8.28
  • IMAB $1.04
  • Average True Range (ATR)
  • SLNG 0.69
  • IMAB 0.06
  • MACD
  • SLNG 0.05
  • IMAB -0.01
  • Stochastic Oscillator
  • SLNG 79.55
  • IMAB 19.88

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About IMAB I-MAB

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).

Share on Social Networks: